Use of antidepressants and the risk of breast cancer: A meta-analysis

Breast Cancer Research and Treatment

Volumn 136, Issue 3, 2012, Pages 635-645

  Eom, Chun Sick ^a   Park, Sang Min ^b   Cho, Kyung Hwan ^c  

^a Hallym University   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Korea University Ansan Hospital   (South Korea)

Author keywords

Antidepressants; Breast cancer; Meta analysis; Selective serotonin reuptake inhibitors; Tricyclic antidepressants

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DATABASE; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; TREATMENT DURATION; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; PUBLISHING; RISK; RISK ASSESSMENT;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BREAST NEOPLASMS; FEMALE; HUMANS; ODDS RATIO; PUBLICATION BIAS; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS;

EID: 84878756216     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2307-y     Document Type: Review

References (66)

1. McPherson K, Steel CM, Dixon JM (2000) ABC of breast diseases. Breast cancer - epidemiology, risk factors, and genetics. BMJ 321(7261):624-628
2. Breast Cancer Statistics Worldwide (2012) http://www. worldwidebreastcancercom/learn/breast-cancer-statistics-worldwide/. Accessed July 2012 [Internet]
3. Meijer WE, Heerdink ER, Leufkens HG, Herings RM, Egberts AC, Nolen WA (2004) Incidence and determinants of long-term use of antidepressants. Eur J Clin Pharmacol 60(1):57-61
4. Worldwide Info Forum (2012) http://wwwworldwideinfoforumcom/forums/ antidepressant-use-doubles-html. Accessed July 2012 [Internet]
5. Brandes LJ, Arron RJ, Bogdanovic RP, Tong J, Zaborniak CL, Hogg GR, Warrington RC, Fang W, LaBella FS (1992) Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res 52(13):3796-3800
6. Abdul M, Logothetis CJ, Hoosein NM (1995) Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol 154(1):247-250
7. Volpe DA, Ellison CD, Parchment RE, Grieshaber CK, Faustino PJ (2003) Effects of amitriptyline and fluoxetine upon the in vitro proliferation of tumor cell lines. J Exp Therap Oncol 3(4):169-184
8. Nordenberg J, Fenig E, Landau M, Weizman R, Weizman A (1999) Effects of psychotropic drugs on cell proliferation and differentiation. Biochem Pharmacol 58(8):1229-1236
9. Bahl S, Cotterchio M, Kreiger N (2003) Use of antidepressant medications and the possible association with breast cancer risk: a review. Psychother Psychosom 72(4):185-194
10. Lawlor DA, Juni P, Ebrahim S, Egger M (2003) Systematic review of the epidemiologic and trial evidence of an association between antidepressant medication and breast cancer. J Clin Epidemiol 56(2):155-163
11. Coogan PF (2006) Review of the epidemiological literature on antidepressant use and breast cancer risk. Expert Rev Neurother 6(9):1363-1374
12. Wells G, Shea B, O'Connell D, et al. (2012) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute, Ottawa, ON. www.ohri.ca/programs/clinical- epidemiology/oxford.asp. Accessed June 2012 [Internet]
13. Mayo Clinic Staff (2012) Risk factors of breast cancer. Mayo Clinic. http://www.mayoclinic.com/health/breast-cancer/DS00328/DSECTION=risk-factors. Accessed June 2012 [Internet]
14. WebMD (2012) Risk factors for breast cancer. WebMD http://www.webmd.com/ breast-cancer/guide/overview-risks-breast-cancer. Accessed June 2012 [Internet]
15. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539-1558
16. Thompson SG, Higgins JPT (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21:1559-1573
17. Kelly JP, Rosenberg L, Palmer JR, Rao RS, Strom BL, Stolley PD, Zauber AG, Shapiro S (1999) Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am J Epidemiol 150(8):861-868
18. Cotterchio M, Kreiger N, Darlington G, Steingart A (2000) Antidepressant medication use and breast cancer risk. Am J Epidemiol 151(10):951-957
19. Kato I, Zeleniuch-Jacquotte A, Toniolo PG, Akhmedkhanov A, Koenig K, Shore RE (2000) Psychotropic medication use and risk of hormone-related cancers: the New York University Women's Health Study. J Public Health Med 22(2):155-160
20. Wang PS, Walker AM, Tsuang MT, Orav EJ, Levin R, Avorn J (2001) Antidepressant use and the risk of breast cancer: a non-association. J Clin Epidemiol 54(7):728-734
21. Moorman PG, Grubber JM, Millikan RC, Newman B (2003) Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. Epidemiology 14(3):307-314
22. Steingart A, Cotterchio M, Kreiger N, Sloan M (2003) Antidepressant medication use and breast cancer risk: a case-control study. Int J Epidemiol 32(6):961-966
23. Coogan PF, Palmer JR, Strom BL, Rosenberg L (2005) Use of selective serotonin reuptake inhibitors and the risk of breast cancer. Am J Epidemiol 162(9):835-838
24. Gonzalez-Perez A, Garcia Rodriguez LA (2005) Breast cancer risk among users of antidepressant medications. Epidemiology 16(1):101-105
25. Haque R, Enger SM, Chen W, Petitti DB (2005) Breast cancer risk in a large cohort of female antidepressant medication users. Cancer Lett 221(1):61-65
26. Chien C, Li CI, Heckbert SR, Malone KE, Boudreau DM, Daling JR (2006) Antidepressant use and breast cancer risk. Breast Cancer Res Treat 95(2):130-140
27. Fulton-Kehoe D, Rossing MA, Rutter C, Mandelson MT, Weiss NS (2006) Use of antidepressant medications in relation to the incidence of breast cancer. Br J Cancer 94(7):1071-1078
28. Tamim H, Boivin JF, Hanley J, Stang M, Collet JP (2006) Risk of breast cancer in association with exposure to two different groups of tricyclic antidepressants. Pharmacoepidemiol Drug Saf 15(10):689-697
29. Davis S, Mirick DK (2007) Medication use and the risk of breast cancer. Eur J Epidemiol 22(5):319-325
30. Coogan PF, Strom BL, Rosenberg L (2008) SSRI use and breast cancer risk by hormone receptor status. Breast Cancer Res Treat 109(3):527-531
31. Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb PA (2009) Antidepressant medication use and breast cancer risk. Pharmacoepidemiol Drug Saf 18(4):284-290
32. Ashbury JE, Levesque LE, Beck PA, Aronson KJ (2010) A population-based case-control study of Selective Serotonin Reuptake Inhibitors (SSRIs) and breast cancer: The impact of duration of use, cumulative dose and latency. BMC Med 8:90
33. Walker AJ, Card T, Bates TE, Muir K (2011) Tricyclic antidepressants and the incidence of certain cancers: a study using the GPRD. Br J Cancer 104(1):193-197
34. Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A, Wahlbeck K, Tiihonen J (2010) Incidence of cancer and antidepressant medication: record linkage study. Int J Cancer 126(1):285-296
35. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE (2004) Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 64(18):6814-6819
36. Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, Rosner B, Speizer FE (1999) Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 91(7):629-634
37. Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE (2000) A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev 9(6):575-579
38. Wang DY, De Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Fentiman IS, Hayward JL, Millis RR (1992) Relationship of blood prolactin levels and the risk of subsequent breast cancer. Int J Epidemiol 21(2):214-221
39. Welsch CW, Nagasawa H (1977) Prolactin and murine mammary tumorigenesis: a review. Cancer Res 37(4):951-963
40. Kiss R, de Launoit Y, L'Hermite-Baleriaux M, L'Hermite M, Paridaens RJ, Danguy AJ, Pasteels JL (1987) Effect of prolactin and estradiol on cell proliferation in the uterus and the MXT mouse mammary neoplasm. J Natl Cancer Inst 78(5):993-998
41. Cowen PJ, Sargent PA (1997) Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission. J Psychopharmacol 11(4):345-348
42. Turkington RW (1972) Prolactin secretion in patients treated with various drugs: phenothiazines, tricyclic antidepressants, reserpine, and methyldopa. Arch Intern Med 130(3):349-354
43. Krulich L (1975) The effect of a serotonin uptake inhibitor (Lilly 110140) on the secretion of prolactin in the rat. Life Sci 17(7):1141-1144
44. Urban RJ, Veldhuis JD (1991) A selective serotonin reuptake inhibitor, fluoxetine hydrochloride, modulates the pulsatile release of prolactin in postmenopausal women. Am J Obstet Gynecol 164(1 Pt 1):147-152
45. Leatherman ME, Ekstrom RD, Corrigan M, Carson SW, Mason G, Golden RN (1993) Central serotonergic changes following antidepressant treatment: a neuroendocrine assessment. Psychopharmacol Bull 29(2):149-154
46. Dulchin MC, Oquendo MA, Malone KM, Ellis SP, Li S, Mann JJ (2001) Prolactin response to dl-fenfluramine challenge before and after treatment with paroxetine. Neuropsychopharmacology 25(3):395-401
47. Molitch ME (2005) Medication-induced hyperprolactinemia. Mayo Clinic Proc 80(8):1050-1057
48. Hermann B, Vollmer I, Holsboer F, Rupprecht R (2001) Antidepressants do not modulate estrogen receptor alpha-mediated gene expression. J Neural Transm 108(10):1197-1202
49. Feuer G (1983) Drug control of steroid metabolism by the hepatic endoplasmic reticulum. Drug Metab Rev 14(6):1119-1144
50. Kuiper GG, Shughrue PJ, Merchenthaler I, Gustafsson JA (1998) The estrogen receptor beta subtype: a novel mediator of estrogen action in neuroendocrine systems. Front Neuroendocrinol 19(4):253-286
51. Miller AH, Spencer RL, McEwen BS, Stein M (1993) Depression, adrenal steroids, and the immune system. Ann Med 25(5):481-487
52. Stein M, Miller AH, Trestman RL (1991) Depression, the immune system, and health and illness. Findings in search of meaning. Arch Gen Psychiatry 48(2):171-177
53. Eisen JN, Irwin J, Quay J, Livnat S (1989) The effect of antidepressants on immune function in mice. Biol Psychiatry 26(8):805-817
54. Laudenslager ML, Clarke AS (2000) Antidepressant treatment during social challenge prior to 1 year of age affects immune and endocrine responses in adult macaques. Psychiatry Res 95(1):25-34
55. Brandes LJ, Bogdanovic RP, Cawker MD, LaBella FS (1987) Histamine and growth: interaction of antiestrogen binding site ligands with a novel histamine site that may be associated with calcium channels. Cancer Res 47(15):4025-4031
56. Brandes LJ, LaBella FS, Glavin GB, Paraskevas F, Saxena SP, McNicol A, Gerrard JM (1990) Histamine as an intracellular messenger. Biochem Pharmacol 40(8):1677-1681
57. Psychology Today (2012) Depression hurts the immune system. http://wwwpsychologytodaycom/articles/200312/depression-hurts-the-immune-system. Accessed July 2012 [Internet]
58. Basso AM, Depiante-Depaoli M, Molina VA (1992) Chronic variable stress facilitates tumoral growth: reversal by imipramine administration. Life Sci 50(23):1789-1796
59. Satin JR, Linden W, Phillips MJ (2009) Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 115(22):5349-5361
60. Giese-Davis J, Collie K, Rancourt KM, Neri E, Kraemer HC, Spiegel D (2011) Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol 29(4):413-420
61. Spiegel D, Giese-Davis J (2003) Depression and cancer: mechanisms and disease progression. Biol Psychiatry 54(3):269-282
62. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS (2011) Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 183(3):310-319
63. Eom CS, Park SM, Myung SK, Yun JM, Ahn JS (2011) Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med 9(3):257-267
64. Eom CS, Lee HK, Ye S, Park SM, Cho KH (2012) Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis. J Bone Miner Res 27(5):1186-1195
65. Moride Y, Abenhaim L (1994) Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 47(7):731-737
66. Donaldson LJ, Reckless IP, Scholes S, Mindell JS, Shelton NJ (2008) The epidemiology of fractures in England. J Epidemiol Community Health 62(2):174-180